HistoSonics Raises $250 Million to Expand Edison Cancer Treatment Globally

HistoSonics has secured $250 million in funding to support the commercial and clinical expansion of its Edison histotripsy system, a noninvasive cancer treatment that uses focused sound waves to destroy tumors. The round included investors such as Bezos Expeditions, Thiel Bio, Founders Fund, K5 Global, and Wellington Management, following a recent acquisition of a majority stake that valued the company at $2.25 billion.

The Edison system, which received FDA de novo clearance with backing from Johnson & Johnson, initially targets liver cancers but is being developed for kidney, pancreas, and prostate indications. HistoSonics aims to offer a minimally invasive alternative to surgery, thermal ablation, or radiation, using sound waves to liquefy tumors without cutting or applying heat.

The funds will help HistoSonics expand into international markets, advance ongoing clinical trials, and explore new indications, positioning the company for strategic growth as a privately held entity.

20-10-2025